Immunotherapy of Stage III/IV Melanoma Patients - Full Text View

Purpose

The purpose of this study is to determine whether vaccination with melanoma antigen peptides [Melan-A/Mart-1 (both EAA and ELA), NY-ESO-1b analog, Long NY-ESO-1 LP and MAGE-A10] and Montanide, CpG adjuvants and low dose rIL-2 can induce an immune response in melanoma patients and to assess the safety of this vaccination.

Condition	Intervention	Phase
Melanoma	Biological: Montanide + Melan-A analogue peptide Biological: Montanide + Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide Biological: Montanide + CpG-7909 / PF-3512676+Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide Biological: Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide Biological: Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide + low dose IL-2	Phase I

MedlinePlus related topics:

Cancer Melanoma

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment

Official Title:	Vaccination of Patients With Stage III or IV Malignant Melanoma With Melanoma Antigen Peptides [Melan-A/Mart-1 Analog (ELA), NY-ESO-1b(A) Analog and MAGE-A10] and Montanide Adjuvant

Further study details as provided by Ludwig Institute for Cancer Research:

Primary Outcome Measures:

Safety of the vaccination will be assessed according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) scale [ Time Frame: Duration of study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

In patients with measurable disease, tumor response will be assessed by radiology [ Time Frame: Duration of study ] [ Designated as safety issue: No ]

Estimated Enrollment:	37
Study Start Date:	February 2004
Estimated Study Completion Date:	December 2008
Estimated Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Montanide + Melan-A analogue peptide	Biological: Montanide + Melan-A analogue peptide 1 ml Montanide+ 500 mcg Melan-A analog peptide
2: Experimental Montanide + Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide	Biological: Montanide + Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide 1 ml Montanide + 500 mcg Melan-A analog peptide + 500 mcg NY-ESO-1 analog peptide + 500 mcg Mage10 peptide
3: Experimental Montanide + CpG-7909/PF-3512676+Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide	Biological: Montanide + CpG-7909 / PF-3512676+Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide 1 ml Montanide + 2.5 mg CpG-7909/PF-3512676 + 500 mcg Melan-A analog peptide, 500 mcg + NY-ESO-1 analog peptide + 500 mcg Mage10 peptide
4: Experimental Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide	Biological: Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide 1 ml Montanide + 2.5 mg CpG-7909/PF-3512676 + 100 mcg Melan-A native and analog peptides + 500 mcg NY-ESO-1 long peptide + 100 mcg Mage10 peptide
5: Experimental Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide + low dose IL-2	Biological: Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide + low dose IL-2 1 ml Montanide + 2.5 mg CpG-7909/PF-3512676 + 100 mcg Melan-A native and analog peptides + 500 mcg NY-ESO-1 long peptide + 100 mcg Mage10 peptide + low dose IL-2

Detailed Description:

Current peptide vaccines suffer from low efficiency, since they induce only weak immune activation. We have recently confirmed that in humans the immune response was readily detectable in local lymph nodes while no or only weak activation could be identified in circulating lymphocytes. Increased doses of antigen and adjuvant allow a better extension from local to systemic immune responses.

Group 1 : vaccination with Melan-A analog (ELA) peptide + Montanide
Group 2 : vaccination with Melan-A analog (ELA), NY-ESO-1b analog and MAGE-A10 peptides + Montanide
Group 3: vaccination with Melan-A analog (both EAA and ELA), Mage-A10, NY-ESO-1 peptides+ Montanide + CpG adjuvant
Group 4: vaccination with Melan-A (ELA), Mage-A10,long NY-ESO-1LP peptides + Montanide + CpG
Group 5: vaccination with Melan-A(both EAA and ELA), Mage-A10, long NY-ESO-1 LP peptides + Montanide + CpG + low dose rIL-2

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Histologically confirmed stage III or stage IV melanoma
Tumor expression of Melan-A +/- one of the tumor antigens MAGE-A10, NY-ESO-1, or LAGE-1
Human leukocyte antigen-A2 (HLA-A2) positive

Exclusion Criteria:

Clinically significant heart disease
Serious illnesses, eg, serious infections requiring antibiotics, uncontrolled peptic ulcer, or central nervous system disorders
History of immunodeficiency disease or autoimmune disease
Coagulation or bleeding disorders

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00112242

Locations


Switzerland
	Division of Oncology at the Geneva University Hospital	Active, not recruiting
	Geneva, Switzerland, 1211

Switzerland, Vaud
	Ludwig Institute for Cancer Research + Multidisciplinary Oncology Center at the Centre Hospitalier Universitaire Vaudois	Recruiting
	Lausanne, Vaud, Switzerland, 1011
	Contact: Daniel E. Speiser, MD +41.21.314.01.82 daniel.speiser@hospvd.ch
	Contact: E.
	Sub-Investigator: Daniel E. Speiser, MD

Sponsors and Collaborators

Ludwig Institute for Cancer Research

Investigators


Principal Investigator:	Olivier Michielin, MD	Ludwig Institute for Cancer Research

More Information

Publications:

Speiser DE, Pittet MJ, Rimoldi D, Guillaume P, Luescher IF, Lienard D, Lejeune F, Cerottini JC, Romero P. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin Cancer Biol. 2003 Dec;13(6):461-72. Review.

Lienard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, Zippelius A, Fleischhauer K, Lejeune F, Cerottini JC, Romero P, Speiser DE. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun. 2004 May 19;4:4.

Responsible Party:	Ludwig Institute for Cancer Research ( Ralph Venhaus, MD, Head of Clinical and Regulatory Affairs )
Study ID Numbers:	LUD 2001-003
First Received:	May 31, 2005
Last Updated:	February 1, 2008
ClinicalTrials.gov Identifier:	NCT00112242
Health Authority:	Switzerland: Swissmedic

Keywords provided by Ludwig Institute for Cancer Research:

Immunotherapy

Vaccination

Melanoma

Melan-A/Mart-1 peptide

MAGE-A10 peptide

NY-ESO-1 peptide

Montanide

Study placed in the following topic categories:

Neuroectodermal Tumors

Nevus, Pigmented

Neoplasms, Germ Cell and Embryonal

Neuroepithelioma

Nevus

Neuroendocrine Tumors

Melanoma

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevi and Melanomas

ClinicalTrials.gov processed this record on October 03, 2008

Sponsored by:	Ludwig Institute for Cancer Research
Information provided by:	Ludwig Institute for Cancer Research
ClinicalTrials.gov Identifier:	NCT00112242